Education
About Us
Working with TipRanks
Follow Us
Phreesia (PHR)
NYSE:PHR
PHR Stock Chart & Stats
$12.33
$0.87(3.22%)
At close: 4:00 PM EST
$12.33
$0.87(3.22%)
Day’s Range― - ―
52-Week Range$11.31 - $32.76
Previous CloseN/A
Volume173.69K
Average Volume (3M)1.73M
Market Cap
$739.72M
Enterprise Value$635.75M
Total Cash (Recent Filing)$106.37M
Total Debt (Recent Filing)$3.48M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Mar 30, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding60,287,003
10 Day Avg. Volume1,616,763
30 Day Avg. Volume1,728,450
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)6.19
Price to Sales (P/S)3.90
P/FCF Ratio197.66
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit2.01
Enterprise Value/Ebitda24.05
Forecast
1Y Price Target
$27.82Price Target Upside125.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)0.52
Revenue Forecast (FY)$552.52M
Bulls Say, Bears Say
Bulls Say
Acquisition And Payments ExpansionThe AccessOne acquisition is expected to broaden payments capabilities with minimal technical integration and contribute accretion to adjusted EBITDA margin in fiscal 2026, diversifying revenue and monetization levers.
Network Advertising And Provider MarketingA new provider-focused marketing program and existing large-pharma relationships position the Network segment to capture shifting advertising spend toward point-of-care channels, potentially increasing revenue per provider.
Profitability And Operating LeverageMargin expansion and stronger operating leverage have shifted the company from earlier losses to healthier profitability, supporting improved free cash flow prospects and a more attractive risk-reward profile.
Bears Say
Margin Timing And Cost HeadwindsRevenue timing issues, higher payroll taxes, and a difficult year-over-year comp are cited as drivers of a sequential margin decline implied in the fiscal 2026 guide, increasing near-term margin uncertainty.
Network Segment Demand UncertaintySoftness in Network Solutions and modest downward revisions to estimates amid a tougher macro backdrop create risk that the segment will underperform previous growth expectations.
Revenue Growth And Guidance RiskSales growth that came in below expectations, combined with management's cautious commentary on pharmaceutical marketing budgets, may keep downward pressure on revenue forecasts and investor sentiment.
Phreesia News
PHR FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest stock price was $11.31 and its highest was $32.76 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is $739.72M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Mar 30, 2026 which is in 27 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on Dec 08, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0 by $0.07.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Undervalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.07.
How many shares outstanding does Phreesia have?
Phreesia has 60,287,003 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of $0.07 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went down -23.31%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in PHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.82 (125.63% Upside)
$27.82 (125.63% Upside)
Blogger Sentiment
Bullish
PHR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.76%
12-Months-Change
Fundamentals
Return on Equity
-1.87%
Trailing 12-Months
Asset Growth
12.71%
Trailing 12-Months
Company Description
Phreesia
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
PHR Company Deck
PHR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, strategic acquisitions, and positive financial metrics, indicating continued momentum and strategic positioning for future growth. However, challenges in network solutions and the financial impact of the AccessOne acquisition present areas to monitor.View all PHR earnings summariesPHR Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
PHR Stock 12 Month Forecast
Average Price Target
$27.82
▲(125.63% Upside)
Technical Analysis
Ownership Overview
6.04% Insiders
35.08% Mutual Funds
17.92% Other Institutional Investors
28.01% Public Companies and Individual Investors